Provide Input

Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

burosumab (Crysvita)

Therapeutic Area: Treatment of X-Linked Hypophosphatemia 
Draft recommendations posted for stakeholder feedback: June 13, 2024
End of feedback period: June 27, 2024
Draft Recommendation

Submit Feedback

 

atogepant (Qulipta)

Therapeutic Area: Migraine, prevention
Draft recommendations posted for stakeholder feedback: June 13, 2024
End of feedback period: June 27, 2024
Draft Recommendation

Submit Feedback

 

pembrolizumab (N/A)

Therapeutic Area: Melanoma (Skin)
Draft recommendations posted for stakeholder feedback: June 6, 2024
End of feedback period: June 20, 2024
Draft Recommendation

Submit Feedback

 

nivolumab and ipilimumab (N/A)

Therapeutic Area: Melanoma (Skin)
Draft recommendations posted for stakeholder feedback: June 6, 2024
End of feedback period: June 20, 2024
Draft Recommendation

Submit Feedback

 

nab-paclitaxel (N/A)

Therapeutic Area: Solid tumours
Draft recommendations posted for stakeholder feedback: June 6, 2024
End of feedback period: June 20, 2024
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Alzheimer's disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Hereditary angioedema (HAE)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Unresectable or metastatic MSI-H or dMMR solid tumors
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: resectable non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Seasonal allergic rhinitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Myelofibrosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: locally advanced unresectable or metastatic urothelial carcinoma (UC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: